Can RIGL's Oncology Portfolio Create Long-Term Value Beyond Tavalisse?
Rigel's Tavalisse drives strong sales, but expansion with Rezlidhia, Gavreto, and pipeline candidates could shape its long-term growth story.
Should Value Investors Buy Rigel Pharmaceuticals ( RIGL ) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Rigel ( RIGL ) Loses 27.0% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Rigel (RIGL) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday - Astera Labs ( NASDAQ:ALAB ) , BGM Group ( NASDAQ:BGM )
U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Wednesday. Shares of Freeport-McMoRan Inc. FCX shares declined 16.4% to $37.94 after the company issued third-quarter sales guidance.
Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?
RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.
CEO At Rigel Pharmaceuticals Acquires Company Stock Options Worth $388K - Rigel Pharmaceuticals ( NASDAQ:RIGL )
A substantial acquisition of company stock options by RAUL RODRIGUEZ, CEO at Rigel Pharmaceuticals RIGL was reported on September 17, based on a new SEC filing. What Happened: In a Form 4 filing with the U.S.
Raymond Furey At Rigel Pharmaceuticals Secures Company Stock Options: $90K Acquired - Rigel Pharmaceuticals ( NASDAQ:RIGL )
A substantial acquisition of company stock options by Raymond Furey, EVP at Rigel Pharmaceuticals RIGL was reported on September 17, based on a new SEC filing. What Happened: Revealed in a Form 4 filing on Wednesday with the U.S.
Lisa Rojkjaer Enhances Portfolio With Rigel Pharmaceuticals Stock Options: $90K Acquired - Rigel Pharmaceuticals ( NASDAQ:RIGL )
A noteworthy insider acquisition was disclosed on September 17, as Rojkjaer, EVP at Rigel Pharmaceuticals RIGL, reported the acquisition of stock options for 7,394 shares. What Happened: Revealed in a Form 4 filing on Wednesday with the U.S.
Significant Move: David Santos Invests $90K In Rigel Pharmaceuticals Stock Options - Rigel Pharmaceuticals ( NASDAQ:RIGL )
On September 17, Santos, EVP at Rigel Pharmaceuticals RIGL, executed a strategic insider move by acquiring stock options for 7,394 shares. What Happened: In a recent Form 4 filing with the U.S.
Dean Schorno Makes Strategic Play: Invests $90K In Rigel Pharmaceuticals Stock Options - Rigel Pharmaceuticals ( NASDAQ:RIGL )
In a new SEC filing on September 17, it was unveiled that Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals RIGL, acquired stock options for 7,394 shares. What Happened: Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals, engaged in a derivative transaction according to ...
Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?
RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.
What Makes Rigel Pharmaceuticals ( RIGL ) a Strong Momentum Stock: Buy Now?
Does Rigel Pharmaceuticals (RIGL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Do Options Traders Know Something About RIGL Stock We Don't?
Investors need to pay close attention to Rigel Pharmaceuticals stock based on the movements in the options market lately.
Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock?
CORT's stock is up 39.6% year to date as relacorilant nears FDA approval for Cushing's syndrome and expands into cancer studies.
Rigel Pharmaceuticals, Inc. ( RIGL ) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU
MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.
SNY's Rilzabrutinib Gets EU Orphan Drug Tag for IgG4-Related Disease
Sanofi wins EMA's orphan drug status for rilzabrutinib to treat IgG4-RD, a chronic, immune-mediated rare disease.
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Earnings Estimates Moving Higher for Rigel ( RIGL ) : Time to Buy?
Rigel Pharmaceuticals (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Best Momentum Stock to Buy for August 8th
RIGL, APG and CLSK made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 8, 2025.
5 Best Stocks With Relative Price Strength to Buy Right Now
LendingTree, RIGL, and others are standing out with strong relative price strength amid market volatility.
New Strong Buy Stocks for August 8th
INFU, RIGL, TROW, MITSY and NTRS have been added to the Zacks Rank #1 (Strong Buy) List on August 8, 2025.
Rigel Pharmaceuticals ( RIGL ) Just Flashed Golden Cross Signal: Do You Buy?
Is it a good or bad thing when a stock experiences a golden cross technical event?
Rigel Pharmaceuticals, Inc. ( RIGL ) Hits Fresh High: Is There Still Room to Run?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Rigel ( RIGL ) Q2 Revenue Jumps 176%
Rigel Pharmaceuticals ( NASDAQ:RIGL ) , a biopharmaceutical company known for developing and selling treatments for cancer and rare blood disorders, released its second quarter 2025 results on August 5, 2025. The most significant takeaway from the earnings release was that GAAP revenue and net ...
Rigel Pharmaceuticals ( RIGL ) Q2 Earnings and Revenues Surpass Estimates
Rigel (RIGL) delivered earnings and revenue surprises of +66.50% and +28.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical ( COLL ) Q2 Earnings Preview: What's in the Cards?
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Rigel ( RIGL ) Could Beat Earnings Estimates Again
Rigel (RIGL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Rigel ( RIGL ) Climb 69.55% to Reach the Level Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 69.6% in Rigel (RIGL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Investors Undervaluing Rigel Pharmaceuticals ( RIGL ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Rigel Pharmaceuticals ( RIGL ) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Wall Street Analysts See a 71.97% Upside in Rigel ( RIGL ) : Can the Stock Really Move This High?
The consensus price target hints at a 72% upside potential for Rigel (RIGL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Rigel ( RIGL ) Is a Great 'Buy the Bottom' Stock Now
Rigel (RIGL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Is Rigel Pharmaceuticals ( RIGL ) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Earnings Estimates Rising for Rigel ( RIGL ) : Will It Gain?
Rigel (RIGL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Wall Street Analysts Think Rigel ( RIGL ) Could Surge 82.3%: Read This Before Placing a Bet
The mean of analysts' price targets for Rigel (RIGL) points to an 82.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Rockwell Automation Posts Better-Than-Expected Earnings, Joins Oscar Health, Charles River Laboratories, Walt Disney, Voya Financial And Other Big Stocks Moving Higher On Wednesday - Angi ( NASDAQ:ANGI ) , BorgWarner ( NYSE:BWA )
U.S. stocks were higher, with the Dow Jones index gaining around 200 points on Wednesday. Shares of Rockwell Automation, Inc. ROK rose sharply during Wednesday's session after the company reported better-than-expected second-quarter financial results and raised its FY25 adjusted EPS and GAAP EPS ...
Rigel Pharmaceuticals ( RIGL ) Beats Q1 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 350% and 22.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings
BMPC's first-quarter earnings and sales miss estimates. However, shares rally on raised Ayvakit sales guidance for 2025.
Ardelyx ( ARDX ) Reports Q1 Loss, Misses Revenue Estimates
Ardelyx (ARDX) delivered earnings and revenue surprises of -70% and 8.14%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Indivior PLC ( INDV ) Q1 Earnings and Revenues Beat Estimates
Indivior (INDV) delivered earnings and revenue surprises of 86.36% and 11.51%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Rigel ( RIGL ) Upgraded to Buy: What Does It Mean for the Stock?
Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
Wall Street Awaits Trump's Tariff Decision, Digests Mixed Economic Data: What's Driving Markets Wednesday? - SPDR S&P 500 ( ARCA:SPY )
Wall Street digests strong services sector data and weak ADP employment report. Bitcoin is up nearly 5% on the week, as investors look forward to President Trump's White House crypto summit on Friday. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential.
Wall Street Analysts Believe Rigel ( RIGL ) Could Rally 44.93%: Here's is How to Trade
The mean of analysts' price targets for Rigel (RIGL) points to a 44.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
Esperion reports a narrower-than-expected loss for the fourth quarter of 2024. Revenues lag estimates. Stock up.
Rigel Pharmaceuticals ( RIGL ) Surpasses Q4 Earnings and Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of 45.45% and 0.02%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Stocks Drop As Trade War Escalates: What's Driving Markets Tuesday? - SPDR S&P 500 ( ARCA:SPY )
U.S. stocks drop Tuesday as President Donald Trump's tariffs on key trade partners came into effect. The yield on the US 10-year Treasury note falls to 4.13%, its lowest level since October 2024.
